1. Home
  2. IMMP vs ATGL Comparison

IMMP vs ATGL Comparison

Compare IMMP & ATGL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • IMMP
  • ATGL
  • Stock Information
  • Founded
  • IMMP 1987
  • ATGL 2017
  • Country
  • IMMP Australia
  • ATGL Hong Kong
  • Employees
  • IMMP N/A
  • ATGL N/A
  • Industry
  • IMMP Biotechnology: Pharmaceutical Preparations
  • ATGL
  • Sector
  • IMMP Health Care
  • ATGL
  • Exchange
  • IMMP Nasdaq
  • ATGL Nasdaq
  • Market Cap
  • IMMP 251.8M
  • ATGL 299.1M
  • IPO Year
  • IMMP N/A
  • ATGL 2023
  • Fundamental
  • Price
  • IMMP $1.64
  • ATGL $33.93
  • Analyst Decision
  • IMMP Buy
  • ATGL
  • Analyst Count
  • IMMP 1
  • ATGL 0
  • Target Price
  • IMMP $7.00
  • ATGL N/A
  • AVG Volume (30 Days)
  • IMMP 87.8K
  • ATGL 14.8K
  • Earning Date
  • IMMP 10-21-2025
  • ATGL 01-01-0001
  • Dividend Yield
  • IMMP N/A
  • ATGL N/A
  • EPS Growth
  • IMMP N/A
  • ATGL N/A
  • EPS
  • IMMP N/A
  • ATGL N/A
  • Revenue
  • IMMP $3,306,742.00
  • ATGL $1,590,148.00
  • Revenue This Year
  • IMMP N/A
  • ATGL N/A
  • Revenue Next Year
  • IMMP $725.37
  • ATGL N/A
  • P/E Ratio
  • IMMP N/A
  • ATGL N/A
  • Revenue Growth
  • IMMP 31.28
  • ATGL 42.17
  • 52 Week Low
  • IMMP $1.32
  • ATGL $1.15
  • 52 Week High
  • IMMP $2.71
  • ATGL $57.32
  • Technical
  • Relative Strength Index (RSI)
  • IMMP 46.06
  • ATGL 62.64
  • Support Level
  • IMMP $1.60
  • ATGL $28.00
  • Resistance Level
  • IMMP $1.68
  • ATGL $33.88
  • Average True Range (ATR)
  • IMMP 0.07
  • ATGL 3.60
  • MACD
  • IMMP -0.00
  • ATGL 0.12
  • Stochastic Oscillator
  • IMMP 28.12
  • ATGL 76.38

About IMMP Immutep Limited

Immutep Ltd is a globally active biotechnology company developing immunotherapy products for cancer and autoimmune diseases. Its main product is IMP321, which involves clinical development for the treatment of cancer indications. The company is also focused on the development of other products, which include IMP701, which is a blocking anti-LAG-3 antibody for cancer and is in Phase I of its clinical trials, and CVac, which is a personalized immunocellular therapeutic investigated for the treatment of epithelial cancer. Geographically all the business activity of the firm is functioned through the region of Australia.

About ATGL Alpha Technology Group Limited

Alpha Technology Group Ltd operates through its subsidiaries, which are established cloud-based IT solution service providers in Hong Kong. Its Operating Subsidiaries utilize its analytic skills, programming skills, artificial intelligence technologies and technological know-how to provide comprehensive solutions designed to optimize the business performance of customers, meet various industry-specific operational challenges of customers and create new business opportunities for customers. The Operating Subsidiaries provide services for customers from a variety of industries, including consulting, real estate, architectural design, carpark management, electronic payment services, logistics, investments, retail, textiles, wholesale and distribution, etc.

Share on Social Networks: